The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Open accessAbstract
Tumour cells, with stem-like properties, are highly aggressive and often show drug resistance. Here, we reveal that integrin α(v)β₃ serves as a marker of breast, lung and pancreatic carcinomas with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib. This was observed in vitro and in mice bearing patient-derived tumour xenografts or in clinical specimens from lung cancer patients who had progressed on erlotinib. Mechanistically, α(v)β₃, in the unliganded state, recruits KRAS and RalB to the tumour cell plasma membrane, leading to the activation of TBK1 and NF-κB. In fact, α(v)β₃ expression and the resulting KRAS-RalB-NF-κB pathway were both necessary and sufficient for tumour initiation, anchorage independence, self-renewal and erlotinib resistance. Pharmacological targeting of this pathway with bortezomib reversed both tumour stemness and erlotinib resistance. These findings not only identify α(v)β₃ as a marker/driver of carcinoma stemness but also reveal a therapeutic strategy to sensitize such tumours to RTK inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, integrin αvβ3 can induce apoptosis (Stupack et al., 2001), tumor progression (Desgrosellier et al., 2009), and tumor stemness (Seguin et al., 2014) in an anchorage-independent manner.”
From Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway (2017) · cites this paper as Seguin et al., 2014
In the citing paper
“Interestingly, integrins can also mediate signaling cascades independent of ligand binding.”
From Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway (2017) · cites this paper as Seguin et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2748 · Cited by 3,815
Self-citationTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2499 · Cited by 3,501
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Self-citationHermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M. O., Bruns, C. J., & Heeschen, C. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,946
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Flagged first, then by citations
Cited by
Sorted by citations
Identification of the tumour transition states occurring during EMT
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Keymeulen, A. V., Brown, D. V., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,556
Every step of the way: integrins in cancer progression and metastasis
Hamidi, H., & Ivaska, J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0038-z · Cited by 1,493
Cooper, J. M., & Giancotti, F. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.007 · Cited by 967
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 904
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 795
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
Seguin, L., Desgrosellier, J. S., Weis, S. M., & Cheresh, D. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.006 · Cited by 685
Self-citationCancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 656
Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 518
Exploring the Role of RGD-Recognizing Integrins in Cancer
Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H., Schwaiger, M., Weinmüller, M., Räder, A. F. B., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 441
Tumor microenvironment and cancer therapy resistance
Sun, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.044 · Cited by 391
Drug resistance and Cancer stem cells
Li, Y., Wang, Z., Ajani, J. A., & Song, S. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-020-00627-5 · Cited by 351
Patient-centric trials for therapeutic development in precision oncology
Biankin, A. V., Piantadosi, S., & Hollingsworth, S. J. (2015) · Nature · doi:10.1038/nature15819 · Cited by 286
Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis
Laubli, H. P., & Borsig, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02120 · Cited by 281
The NF-κB Pathway and Cancer Stem Cells
Rinkenbaugh, A. L., & Baldwin, A. S. (2016) · Cells · doi:10.3390/cells5020016 · Cited by 265
Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy
Carlson, P., Dasgupta, A., Grzelak, C. A., Kim, J., Barrett, A. S., Coleman, I. M., Shor, R. E., Goddard, E. T., Dai, J., Schweitzer, E. M., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0267-0 · Cited by 248
Self-citationZhang, P., Li, K.-S., Shen, Y.-H., Gao, P.-T., Dong, Z.-R., Cai, J.-B., Zhang, C., Huang, X.-Y., Tian, M.-X., Zq, H., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.324 · Cited by 248
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Ireland, L., Santos, A., Ahmed, M. S., Rainer, C., Nielsen, S. R., Quaranta, V., Weyer-Czernilofsky, U., Engle, D. D., Pérez-Mancera, P. A., Coupland, S. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1201 · Cited by 248
Self-citationMurtuza, A., Bulbul, A., Shen, J. P., Keshavarzian, P., Woodward, B. D., Lopez-Diaz, F. J., Lippman, S. M., & Husain, H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1281 · Cited by 226
Self-citationEGFR and NF-κB: partners in cancer
Shostak, K., & Chariot, A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.001 · Cited by 222
PHGDH heterogeneity potentiates cancer cell dissemination and metastasis
Rossi, M., Altea‐Manzano, P., Demicco, M., Doglioni, G., Bornes, L., Fukano, M., Vandekeere, A., Cuadros, A. M., Fernández-García, J., Riera‐Domingo, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04758-2 · Cited by 220
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W. Q., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 218
Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway
Rapisarda, V., Borghesan, M., Miguela, V., Encheva, V., Snijders, A. P., Lujambio, A., & O’Loghlen, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.012 · Cited by 190
Shen, M., Jiang, Y., Wei, Y., Ell, B. J., Sheng, X., Esposito, M., Kang, J., Hang, X., Zheng, H., Rowicki, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.016 · Cited by 203
Integrins in cancer: Emerging mechanisms and therapeutic opportunities
Liu, F., Wu, Q., Dong, Z., & Liu, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108458 · Cited by 202
METTL1‐m7G‐EGFR/EFEMP1 axis promotes the bladder cancer development
Ying, X., Liu, B., Yuan, Z., Huang, Y., Chen, C., Xu, J., Zhang, H., Qi, D., Yang, S., Lin, S., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.675 · Cited by 188
Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression
Seager, R. J., Hajal, C., Spill, F., Kamm, R. D., & Zaman, M. H. (2017) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/aa7e86 · Cited by 192
Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis
Zhu, Z., Mesci, P., Bernatchez, J. A., Gimple, R. C., Wang, X., Schafer, S. T., Wettersten, H. I., Beck, S., Clark, A. E., Wu, Q., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2019.11.016 · Cited by 191
Self-citationLuo, J., Yao, J., Deng, X., Zheng, X., Jia, M., Wang, Y., Huang, Y., & Zhu, J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0694-6 · Cited by 186
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
Basu, S., Cheriyamundath, S., & Ben‐Ze'ev, A. (2018) · F1000Research · doi:10.12688/f1000research.15782.1 · Cited by 179
Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
Alday-Parejo, B., Stupp, R., & Rüegg, C. (2019) · Cancers · doi:10.3390/cancers11070978 · Cited by 181
Pearson, J. D., Huang, K., Pacal, M., McCurdy, S. R., Lü, S., Aubry, A., Yu, T., Wadosky, K. M., Zhang, L., Wang, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.016 · Cited by 178
Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
Seguin, L., Durandy, M., & Féral, C. C. (2022) · Cancers · doi:10.3390/cancers14071759 · Cited by 188
Self-citationThe paradoxical functions of EGFR during breast cancer progression
Ali, R., & Wendt, M. K. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.42 · Cited by 170
Wu, B., Shi, X., Jiang, M., & Liu, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01748-4 · Cited by 181
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
Cosset, E. C., Ilmjärv, S., Dutoit, V., Elliott, K. C., Schalscha, T. V., Camargo, M. F., Reiss, A., Moroishi, T., Seguin, L., Gomez, G. G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.016 · Cited by 172
Self-citationFrom transformation to metastasis: deconstructing the extracellular matrix in breast cancer
Kaushik, S., Pickup, M. W., & Weaver, V. M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9650-0 · Cited by 174
Role of p38 MAP kinase in cancer stem cells and metastasis
Kudaravalli, S., den Hollander, P., & Mani, S. A. (2022) · Oncogene · doi:10.1038/s41388-022-02329-3 · Cited by 158
Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Wang, Q., Shi, Y.-L., Zhou, K., Wang, L.-L., Yan, Z.-X., Liu, Y.-L., Xu, L.-L., Zhao, S.-W., Chu, H.-L., Shi, T.-T., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0776-6 · Cited by 147
Galectin-3 and cancer stemness
Nangia‐Makker, P., Hogan, V. A., & Raz, A. (2018) · Glycobiology · doi:10.1093/glycob/cwy001 · Cited by 147
The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas
Fedele, M., Cerchia, L., & Chiappetta, G. (2017) · Cancers · doi:10.3390/cancers9100134 · Cited by 146
Wu, X., Cai, J., Zuo, Z., & Li, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108708 · Cited by 142
Prescott, J. A., & Cook, S. J. (2018) · Cells · doi:10.3390/cells7090115 · Cited by 141
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 142
EGFR-mediated autophagy in tumourigenesis and therapeutic resistance
Wu, M., & Zhang, P. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.030 · Cited by 126
Extracellular Matrix Remodeling and Stiffening Modulate Tumor Phenotype and Treatment Response
Leight, J. L., Drain, A. P., & Weaver, V. M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034431 · Cited by 131
The Biological Functions and Clinical Applications of Integrins in Cancers
Su, C., Li, J., Zhang, L.-L., Wang, H., Wang, F., Tao, Y., Wang, Y., Guo, Q., Li, J., Liu, Y., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.579068 · Cited by 117
Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame
Gentry, L. R., Martin, T. D., Reiner, D. J., & Der, C. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.09.004 · Cited by 116
Wang, M., Han, J., Marcar, L., Black, J. C., Liu, Q., Li, X., Nagulapalli, K., Sequist, L. V. D., Mak, R. H., Benes, C. H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0808 · Cited by 111
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
Blandin, A.-F., Renner, G., Lehmann, M., Lelong-Rebel, I. H., Martin, S., & Dontenwill, M. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00279 · Cited by 105
Koga, Y., & Ochiai, A. (2019) · Cells · doi:10.3390/cells8050418 · Cited by 111
Nguyen, L. V., Cox, C. L., Eirew, P. D., Knapp, D. J. H. F., Pellacani, D., Kannan, N., Carles, A., Moksa, M., Balani, S., Shah, S. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6871 · Cited by 107
Macropinocytosis: Insights from immunology and cancer
Stow, J. L., Hung, Y., & Wall, A. A. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.06.005 · Cited by 95
Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers
Seguin, L., Camargo, M. F., Wettersten, H. I., Kato, S., Desgrosellier, J. S., Schalscha, T. V., Elliott, K. C., Cosset, E. C., Lesperance, J., Weis, S. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0539 · Cited by 103
Self-citationYue, J., Lv, D., Wang, C., Li, L., Zhao, Q., Chen, H., & Xu, L. (2018) · Oncogene · doi:10.1038/s41388-018-0276-2 · Cited by 102
Photodynamic Therapy and the Biophysics of the Tumor Microenvironment
Sorrin, A. J., Ruhi, M. K., Ferlic, N. A., Karimnia, V., Polacheck, W. J., Celli, J. P., Huang, H., & Rizvi, I. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13209 · Cited by 104
NF-κB signaling in cancer stem cells: a promising therapeutic target?
Vázquez-Santillán, K., Meléndez-Zajgla, J., Jiménez-Hernández, L., Martinez‐Ruíz, G. U., & Maldonado, V. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0236-6 · Cited by 103
Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy
Ebrahimi, N., Abdulwahid, A. R. R., Mansouri, A., Karimi, N., Bostani, R. J., Beiranvand, S., Adelian, S., Khorram, R., Vafadar, R., Hamblin, M. R., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05098-8 · Cited by 101
PI 3K/Akt/ mTOR pathway dual inhibitor BEZ 235 suppresses the stemness of colon cancer stem cells
Chen, J., Shao, R., Li, F., Monteiro, M. J., Liu, J., Xu, Z. P., & Gu, W. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12493 · Cited by 95
Macropinocytosis in Cancer: A Complex Signaling Network
Zhang, Y., & Commisso, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.04.002 · Cited by 94
Novel Galectin-3 Roles in Neurogenesis, Inflammation and Neurological Diseases
Soares, L. C., Al‐Dalahmah, O., Hillis, J. M., Young, C. C., Asbed, I., Sakaguchi, M., O’Neill, E. E., & Szele, F. G. (2021) · Cells · doi:10.3390/cells10113047 · Cited by 96
Integrin αvβ3 Drives Slug Activation and Stemness in the Pregnant and Neoplastic Mammary Gland
Desgrosellier, J. S., Lesperance, J., Seguin, L., Gozo, M. C., Kato, S., Franovic, A., Yebra, M., Shattil, S. J., & Cheresh, D. A. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.06.005 · Cited by 95
Self-citationSeo, H. A., Moeng, S., Sim, S., Kuh, H. J., Choi, S. Y., & Park, J. K. (2019) · Cells · doi:10.3390/cells9010029 · Cited by 93
Camorani, S., Crescenzi, E., Gramanzini, M., Fedele, M., Zannetti, A., & Cerchia, L. (2017) · Scientific Reports · doi:10.1038/srep46659 · Cited by 92
PAKs in Human Cancer Progression
Kumar, R., & Li, D.-Q. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.002 · Cited by 90
LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating ITGAV transcription
Kang, C. L., Qi, B., Cai, Q., Fu, L., Ying, Y., Tang, C., Zhu, P., Chen, Q. W., Pan, J., Chen, M. H., et al. (2019) · Theranostics · doi:10.7150/thno.32854 · Cited by 89
Integrins regulate stemness in solid tumor: an emerging therapeutic target
Xiong, J., Yan, L., Zou, C., Wang, K., Chen, M., Xu, B., Zhou, Z., & Zhang, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01192-1 · Cited by 92
αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
Vannini, A., Leoni, V., Barboni, C., Sanapo, M., Zaghini, A., Malatesta, P., Campadelli‐Fiume, G., & Gianni, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901931116 · Cited by 89
The challenges and opportunities of αvβ3-based therapeutics in cancer: From bench to clinical trials
Gu, Y., Dong, B., Xu, H., Qiu, Z., Zhang, J., Zhang, M., Liu, H., Pang, X., & Cui, Y. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106694 · Cited by 89
Cancer stem cell drugs target K-ras signaling in a stemness context
Najumudeen, A. K., Jaiswal, A., Lectez, B. L. P., Oetken-Lindholm, C., Guzmán, C., Siljamäki, E., Posada, I. M. D., Lacey, E., Aittokallio, T. A., & Abankwa, D. (2016) · Oncogene · doi:10.1038/onc.2016.59 · Cited by 84
Kwon, Y.-J., Petrie, K. R., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0980-t · Cited by 83
Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer
Silva, E. C. D., Dontenwill, M., Choulier, L., & Lehmann, M. (2019) · Cancers · doi:10.3390/cancers11050692 · Cited by 81
Collective cancer invasion forms an integrin-dependent radioresistant niche
Haeger, A., Alexander, S., Vullings, M., Kaiser, F. M. P., Hulsbergen-Veelken, C. A. R., Flucke, U. E., Koehl, G. E., Hirschberg, M., Flentje, M. P., Hoffman, R. M., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181184 · Cited by 86
Liang, S.-Q., Marti, T. M., Dorn, P., Froment, L., Hall, S., Berezowska, S., Kocher, G. J., Schmid, R. A., & Peng, R. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.195 · Cited by 79
Qiu, S., Deng, L., Liao, X., Nie, L., Qi, F., Jin, K., Tu, X., Zheng, X. S., Li, J., Liu, L., et al. (2019) · Cancer Science · doi:10.1111/cas.14078 · Cited by 82
ITGB3/CD61: a hub modulator and target in the tumor microenvironment.
Zhu, C., Kong, Z., Wang, B., Cheng, W., Wu, A., & Meng, X. (2019) · Europe PMC (PubMed Central) · Cited by 76
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 73
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop
Shi, L., Wang, Y., Lü, Z., Zhang, H., Zhuang, N., Wang, B., Song, Z., Chen, G., Huang, C., Xu, D., et al. (2016) · Oncogene · doi:10.1038/onc.2016.332 · Cited by 71
β1 and β3 integrins in breast, prostate and pancreatic cancer: A novel implication (Review)
Pan, B., Guo, J., Liao, Q., & Zhao, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.8076 · Cited by 69
A cell–ECM screening method to predict breast cancer metastasis
Barney, L. E., Dandley, E. C., Jansen, L. E., Reich, N. G., Mercurio, A. M., & Peyton, S. R. (2014) · Integrative Biology · doi:10.1039/c4ib00218k · Cited by 67
Precision Oncology: Between Vaguely Right and Precisely Wrong
Brock, A., & Huang, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0448 · Cited by 71
Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
Echavidre, W., Picco, V., Faraggi, M., & Montemagno, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051053 · Cited by 66
Zhang, K., Myllymäki, S.-M., Gao, P. H., Devarajan, R., Kytölä, V., Nykter, M., Wei, G., & Manninen, A. (2017) · Oncogene · doi:10.1038/onc.2017.177 · Cited by 65
Tang, Y.-A., Chen, C.-H., Sun, H. S., Cheng, C.-P., Tseng, V. S. M., Hsu, H., Su, W., Lai, W., & Wang, Y. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv024 · Cited by 64
Zhong, C., Tao, B., Tang, F., Yang, X., Peng, T., You, J., Xia, K., Xia, X., Chen, L., & Peng, L. (2020) · Theranostics · doi:10.7150/thno.50613 · Cited by 64
Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Lambert, A. W., Wong, C. K., Ozturk, S., Papageorgis, P., Raghunathan, R., Alekseyev, Y. O., Gower, A. C., Reinhard, B. M., Abdolmaleky, H. M., & Thiagalingam, S. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0079 · Cited by 63
Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Candelotti, E., Vito, P. D., Ahmed, R. G., Luly, P., Davis, P. J., Pedersen, J. Z., Lin, H., & Incerpi, S. (2015) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152221501150710131534 · Cited by 61
Club cells form lung adenocarcinomas and maintain the alveoli of adult mice
Σπέλλα, Μ., Lilis, I., Pepe, M. A. A., Chen, Y., Armaka, M., Lamort, A., Zazara, D. E., Roumelioti, F., Vreka, M., Kanellakis, N. I., et al. (2019) · eLife · doi:10.7554/elife.45571 · Cited by 59
Functional and clinical characteristics of focal adhesion kinases in cancer progression
Zhang, Z., Li, J., Jiao, S., Han, G., Zhu, J., & Liu, T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1040311 · Cited by 66
Pleural involvement in lung cancer.
Agalioti, T., Giannou, A. D., & Stathopoulos, G. T. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2015.04.23 · Cited by 61
Carino, A., Graziosi, L., D’Amore, C., Cipriani, S., Marchianò, S., Marino, E., Zampella, A., Rende, M., Mosci, P., Distrutti, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10477 · Cited by 62
The roles of integrins in cancer
Valdembri, D., & Serini, G. (2021) · Faculty Reviews · doi:10.12703/r/10-45 · Cited by 62
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zhang, Z., Zhang, H., Liao, X., & Tsai, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147676 · Cited by 62
Ral signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58
The Future of Patient-Derived Tumor Xenografts in Cancer Treatment
Sia, D., Moeini, A., Labgaa, I., & Villanueva, A. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.102 · Cited by 58
Cazzanelli, G., Pereira, F. D. S., Alves, S., Francisco, R., Azevedo, L., Carvalho, P. D., Almeida, A. F., Côrte‐Real, M., Oliveira, M. J., Lucas, C., et al. (2018) · Cells · doi:10.3390/cells7020014 · Cited by 60
The pervasiveness of macropinocytosis in oncological malignancies
Commisso, C. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0153 · Cited by 57
Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior
Kumar, V. E., Nambiar, R., Souza, C. D., Nguyen, A. D., CHIEN, J. R., & Lam, K. S. (2022) · Cells · doi:10.3390/cells11091403 · Cited by 61
Metadata
- Authors
- Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., Cascone, T., Diao, L., Wang, J., Wistuba, I. I., Heymach, J. V., Lippman, S. M., Desgrosellier, J. S., Anand, S., Weis, S. M., & Cheresh, D. A.
- Affiliations
- University of California San Diego (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Cheresh, David A.
- ORCID
- Venue
- Nature Cell Biology
- Published
- 2014-04-20
- Volume
- 16
- Issue
- 5
- Pages
- 457-468
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- PMC
- PMC4105198
- OpenAlex
- W2029572050
- Cited by
- 374
- References
- 59
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 22 · 2023: 32 · 2022: 27 · 2021: 36 · 2020: 35 · 2019: 41 · 2018: 28 · 2017: 33 · 2016: 40 · 2015: 34 · 2014: 14
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Association pour la Recherche sur le Cancer
- National Institutes of Health
- U.S. Public Health Service (R3750286)
- National Heart, Lung, and Blood Institute (HL 57900, R00HL112962, P01HL057900)
- National Cancer Institute (CA-45726, R01CA045726, CA155620, R01CA155620, R37CA050286, R01CA168692, CA168692, P30CA023100, T32CA121938, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- integrin αvβ3, KRAS, RalB, erlotinib resistance, cancer stemness, cancer stem cells, NF-κB activation, TBK1, bortezomib, anchorage-independent growth, self-renewal, tumor initiation, lung cancer, breast cancer, pancreatic cancer
- MeSH terms
- Erlotinib Hydrochloride, Animals, Female, Humans, Lung Neoplasms, Mice, Nude, Phenotype, Proto-Oncogene Proteins, Quinazolines, Time Factors, Transfection, Tumor Cells, Cultured, Neoplastic Stem Cells, Signal Transduction, Randomized Controlled Trials as Topic, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Clinical Trials, Phase II as Topic, Protein Serine-Threonine Kinases, ras Proteins, Spheroids, Cellular, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-rel, ral GTP-Binding Proteins, Xenograft Model Antitumor Assays, RNA Interference, Integrin alphaVbeta3, Integrin beta3, Cell Line, Tumor, Tumor Burden, Protein Kinase Inhibitors, Cell Proliferation, Mice, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
